Treatment of Comorbid Obesity and Major Depressive Disorder: A Prospective Pilot Study for their Combined Treatment by Faulconbridge, Lucy F. et al.
Hindawi Publishing Corporation
Journal of Obesity
Volume 2011, Article ID 870385, 5 pages
doi:10.1155/2011/870385
Research Article
TreatmentofComorbid Obesityand Major Depressive Disorder:
A Prospective Pilot Studyfor their Combined Treatment
Lucy F. Faulconbridge,1 ThomasA.Wadden,1 Robert I. Berkowitz,1,2
Melissa E.Pulcini,1 and ThomasTreadwell3
1Center for Weight and Eating Disorders, Department of Psychiatry, University of Pennsylvania, School of Medicine,
Philadelphia, PA 19104, USA
2Department of Child and Adolescent Psychiatry and Behavioral Sciences, Children’s Hospital of Philadelphia, Philadelphia,
PA 19104, USA
3Center for Cognitive Therapy, Department of Psychiatry, University of Pennsylvania, School of Medicine, Philadelphia,
PA 19104, USA
Correspondence should be addressed to Lucy F. Faulconbridge, lucyhf@mail.med.upenn.edu
Received 20 October 2010; Revised 4 March 2011; Accepted 21 March 2011
Academic Editor: Terry Huang
Copyright © 2011 Lucy F. Faulconbridge et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Background. Obese individuals who suﬀer from major depressive disorder are routinely screened out of weight loss trials.
Treatments targeting obesity and depression concurrently have not been tested. Purpose.T ot e s tt h es h o r t - t e r me ﬃcacy of a
treatment thatcombinedbehavioralweight managementandcognitive behavioraltherapy (CBT)forobese adultswithdepression.
Methods. Twelve obese females diagnosed with major depressive disorder received weekly group behavioral weight management,
combined with CBT for depression, for 16 weeks. Weight, symptoms of depression, and cardiovascular disease (CVD) risk factors
were measured at baseline and week 16. Results. Participants lost 11.4% of initial weight and achieved signiﬁcantimprovements in
symptoms of depression and CVD risk factors. Conclusions. Obese individuals suﬀering from major depressive disorder can lose
weightandachieveimprovementsin symptomsofdepressionandCVD riskfactors with16weeks ofcombinedtreatment. Alarger
randomized controlled trial is needed to establish the eﬃcacy of this treatment.
1.Introduction
Depression and obesity are both associated with an increased
risk of cardiovascular disease [1–3] and with marked impair-
ments in quality of life [4, 5]. These two disorders frequently
cooccur, and each presents a risk for the development of
the other [6, 7]. Despite their cooccurrence, depression and
obesity rarely are treated concurrently, and there are no
models for providing such combined therapy. The absence
of care can be traced to concerns raised by two studies,
conducted in the 1950s, which concluded that dieting
precipitated (or exacerbated) symptoms of depression [8, 9].
Such concerns, however, have little current empirical sup-
port. Studies of obese, mildly depressed individuals treated
in behavioral weight loss trials have revealed satisfactory
weight loss and improvements in symptoms of depression,
as measured by self-report instruments [10]. Studies are
lacking of obese individuals with major depression who
are provided behavioral treatment for both their obesity
and their depression, and in whom mood is assessed by
diagnostic interview.
The present pilot study addressed this important treat-
ment gap by providing obese individuals with major depres-
sive disorder (MDD) a 16-week group treatment program
that combined two evidence-based approaches—cognitive
behavioral therapy (CBT) for depression and behavioral
treatment for obesity. Our primary hypotheses were that,
at the end of treatment, participants would achieve (1) a
mean weight loss ≥5% of initial weight and (2) a clinically
signiﬁcant reduction in depression, deﬁned by a 40%
decrease on the Hamilton Depression Rating Scale (HDRS)
[11].Oursecondaryhypotheseswerethatparticipantswould2 Journal of Obesity
achieve signiﬁcant reductions in cardiovascular (CVD) risk
factors including waist circumference, blood pressure, and
lipids.
2.Methods
Enrollment wasopentomen andwomen,ages18–72yr, who
had a body mass index (BMI) of 30–45kg/m2 and suﬀered
fromMDD.Theyalsowererequiredtohaveatleastoneaddi-
tionalrisk factor forCVD,which includedelevationsin waist
circumference, blood pressure, fasting blood glucose levels,
triglycerides, or reduced HDL cholesterol, as deﬁned by the
National Cholesterol Education Program (Adult Treatment
Panel III) [12]. In addition, type 2 diabetes or medications
forany oftheseconditionswereconsideredCVD risk factors.
Exclusion criteria included a weight loss of ≥5% of initial
weight in the prior 6 months, current individual or group
psychotherapy, or occurrence of a cardiovascular event in
the last 12 months. Participants taking selective serotonin
reuptake inhibitors had to have been on a stable dose for at
least 3 months prior to enrollment; individuals taking other
typesofantidepressantswere excluded(duetotheirpotential
eﬀects on weight). A total of 253 applicants responded
to advertisements in the local media, of whom 202 were
successfully contacted for a phone screening interview. (The
other 51 individuals could not be reached.) Of these 202,
166 were excluded following the phone screen, the majority
of whom did not meet criteria for a current depressive
episode. The remaining 36 applicants were invited to attend
an in-clinic screening visit at which the details of the study
were explained, written informed consent was obtained,
and a clinical psychologist met with participants to assess
the presence of MDD using a Structured Clinical Interview
for the DSM-IV (SCID) [13]. Of these 36, 12 did not
attend the visit, 5 decided they were not interested after
learning more about the study, 4 did not meet the depression
criteria, and 1 required treatment for another psychiatric
disorder. Fourteen participants attended a second screening
visit, which included collection of a fasting blood sample.
One participant later determined that she would not be
able to attend the group meeting when scheduled. A second
participant withdrew from the program because of a family
emergency, immediately before treatment began. This left 12
participants who began the trial. The study’s protocol and
procedureswereapprovedbytheUniversityofPennsylvania’s
Institutional Review Board.
Participants attended 16 weekly, 90-min group sessions
(in groups of 6 participants) led by a clinical psychologist
(LF). Half of each session was devoted to behavioral weight
management skills, based on Brownell’sLEARNProgram for
Weight Management [14]. Participants were weighed each
week, given calorie goals (i.e., 1200–1500kcal/d) based on
their initial weight, encouraged to increase exercise gradually
to 180min/wk, and taught skills such as self-monitoring and
stimulus control. The other half of each session consisted of
group CBT for depression, based on Bieling et al.’s group
treatment for depression [15]. Participants were introduced
to the cognitive model of depression and taught to identify
and modify their negative automatic thoughts and core
beliefs. Participants were weighed at each group session and
completed the Beck Depression Inventory-II (BDI-II) [16]
to track the course of symptoms of depression. The BDI-
II is a 21-item questionnaire that assesses mood over the
previous2weeks. Totalscoresrangefrom0to63,withhigher
values indicating greater symptoms of depression. Scores of
0–13 reﬂect minimal (i.e., subclinical) symptoms, whereas
values of 14–19, 20–29, and ≥30 indicate mild, moderate,
and severe symptoms of depression, respectively.
Participants completed outcomes assessments at baseline
and week 16 at which weight, height, and other characteris-
tics were measured. Body weight was measured on a digital
scale(Detecto,model6800A)whileparticipantsweredressed
in light clothing, without shoes. Height was measured using
a wall-mounted stadiometer (Veeder-Root, Elizabethtown,
NC). Waist circumference and blood pressure were assessed
using methods described previously [17]. Fasting blood
samples were obtained (and analyzed by Quest Diagnostics,
Horsham, PA). Symptoms of depression were assessed using
the HDRS by a trained, independent clinician who was
masked to the aims of the study. The HDRS was the study’s
primary outcome for assessing changes in mood.
Changes in weight, HDRS scores, and CVD risk fac-
tors (from baseline to week 16) were assessed by within-
subjects repeated-measures t-tests. Eleven of 12 participants
completed the study. One participant dropped out at week
12 because of her mother’s declining health; her data
were carried forward from week 11 (i.e., her last in-clinic
w e i g h ta n dB D I - I Is c o r e ) .As e c o n dp a r t i c i p a n tb e c a m e
pregnant at week 14. She continued attending group until
the end of treatment, but no data after her pregnancy
are included in the analyses. A third participant showed
signiﬁcant worsening in symptoms of depression at week
13, at which point treatment was intensiﬁed and therefore
no longer consistent with the study protocol. She received
individual treatment sessions with the study psychologist
(LF), was evaluated by the study psychiatrist (RB), and
was then referred to appropriate adjunctive treatment. (The
participant continued to attend groups until the end of the
study, but her data following treatment intensiﬁcation, at
week 13, were not included in data analysis.).
3.Results
At baseline, the 12 participants had a mean (±SD) age of
45.5 ± 9.3yr , weight of 94.5 ± 15.9kg and BMI of 34.9 ±
4.7kg/m 2. Six participants were non-Hispanic white, ﬁve
were African American, and one was of multiple races. The
baseline HDRS score was 20.2 ± 3.3, indicating moderate to
severe symptoms of depression.
As shown in Figure 1(a), the nine participants who
completed the full study lost 10.4 ± 4.9kg over 16 weeks
(P<. 001), equal to a reduction of 11.4 ± 5.9% of initial
weight (P<. 001). (All of the nine participants lost at least
5% of initial weight.) The mean HDRS score decreased from
20.4±3.7t o9.3±4.9,equalto a mean reductionof11.1±4.8
points (P<. 001). Figure 1(b) presents changes in HDRSJournal of Obesity 3



































































Figure 1: (a) shows mean change in percent of initial weight over 16 weeks of treatment (n = 9). (b) presents changes in HDRS scores for
each participant from baseline to week 16 (n = 9). (c) shows mean change in BDI-II score over 16 weeks of treatment (n = 9).
Table 1:Mean(±SD)changesincardiometabolicriskfactors(N =
9).
Baseline Week 16 Change P-value
Waist (cm) 104.2 ±10.59 3 .6 ±12.71 0 .6 ±6.4 .001
Systolic BP 118.4 ±14.4 110.4 ±12.48 .1 ±8.8 .025
Diastolic BP 72.0 ±8.26 3 .3 ±8.78 .7 ±5.3 .001
Cholesterol
Total (mg/dL) 213.2 ±27.4 182.7 ±22.23 0 .6 ±29.3 .014
HDL (mg/dL) 68.9 ±13.86 1 .0 ±12.77 .9 ±10.5 .055
LDL (mg/dL) 127.0 ±24.8 105.4 ±19.72 1 .6 ±21.3 .001
Triglycerides
(mg/dL) 86.7 ±34.28 1 .1 ±35.85 .6 ±27.6 .562
Glucose (mg/dL) 87.9 ±5.08 2 .8 ±5.05 .1 ±6.4 .042
Insulin (uIU/mL) 7.1 ±5.25 .1 ±4.62 .0 ±3.4 .118
Hs-CRP (mg/L) 5.3 ±5.24 .9 ±3.50 .4 ±3.7 .748
BP: blood pressure; HDL: high density lipoprotein; LDL: low-density
lipoprotein; Hs-CRP: high sensitivity C-reactive protein. P values based on
repeated-measures t -tests.
scores for each participant. Using the criterion of an HDRS
score ≤8[18],six (ofnine)participants (67%)were classiﬁed
as responders (i.e., full remission of depression). All nine
participantswho completedthestudyachievedatleasta 40%
reduction in HDRS scores, and ﬁve achieved at least a 50%
reduction. As shown in Figure 1(c),B D I - I Is c o r e sd e c l i n e d
from 27.9±7.3t o8.9±7.6at week 16, a decline of 19.0±5.3
points (P<. 001).
Data were examined at the time of last observation for
the three participants who did not complete the study. They
lost a mean of7.3±1.5kg,equalto a reductionof7.5 ± 3.5%
ofinitial weight (P<. 001).The mean HDRSscore decreased
from 19.3 ± 2.1t o1 2 .0 ± 14.0. Two of the three participants
achieved an 88.2% and 100% reduction in HDRS scores,
respectively; the third participant showed an increase of
4%. The three participants reported a mean reduction on
the BDI-II of 7.6 ± 16.9 points (i.e., an improvement in
symptoms of depression).
As shown in Table 1, signiﬁcant improvements were
observed in the CVD risk factors examined, with the
exception of triglycerides and HDL cholesterol (the latter
declined rather than increased, as is typical with short-
term caloric restriction [19]). Framingham Risk scores [12]
declined from 4.2% to 1.7% 10-year risk (P<. 01).
Two participants were takingselectiveserotoninreuptake
inhibitors throughout the study. No diﬀerences in changes
in symptoms of depression were observed between these two
participantsandtherestofthegroup.Theydid,however,lose
a smaller percentage of initial weight (6.5% versus 11.3%),
but the limited sample size prevents statistical analysis.
4.Discussion
This is the ﬁrst study of which we are aware to combine
behavioral weight management for obesity with CBT for
depression for obese individuals diagnosed with major
depressive disorder. Participants who completed the study
lost 11.4 ± 5.9% of initial weight in 16 weeks—a loss
comparable to that achieved in nondepressed individuals
after 16 weeks of behavioral treatment [20]. This ﬁnding
contradicts concerns that depressed individuals will not
be able to lose as much weight as their non-depressed
counterparts [21, 22].
As a group, participants also achieved signiﬁcant im-
provements in symptoms of depression, as shown by the
reduction on the HDRS scores. Baseline scores indicative
of moderate to severe symptoms of depression fell at week
16 to levels indicative of mild symptoms, and two thirds
of the participants who completed the study achieved full
remission of depression. Only one participant experienced
worsening mood symptoms. This individual had a long-
standing history of severe, treatment-resistant depression
(including an inpatient hospitalization in the last decade).
Of note, she lost 9.2% of her initial weight in spite of her
worsening aﬀect, and she chose to complete the study. Thus,
for the great majority of our obese individuals with MDD,
moderate weight loss combined with CBT was associated
with improvements, rather than worsening, in symptoms of
depression.
Concerns that depressed individuals cannot adhere to
treatment recommendations or will drop out of treatment
[23] were not supported by this study. Eleven out of 12
participants continued to come to group sessions until the
end of the study (with usable data from nine participants),4 Journal of Obesity
and participants attended 89.6% of possible treatment
sessions.
Priorstudieshaveestablishedthatmoderateweightlosses
(∼5% of initial weight) are suﬃcient to improve CVD
risk factors [24, 25] .O u rp a r t i c i p a n t sa c h i e v e ds i g n i ﬁ c a n t
improvements in waist circumference, diastolic and systolic
blood pressure, and LDL, and total cholesterol. HDL choles-
terol declined signiﬁcantly (rather than increased) at week
16, as usually observed with short-term weight loss [19].
HDL cholesterol typically increases over the long term, after
caloric restriction is terminated.
This study had numerous limitations, including a small
samplesizeandalackofappropriatecontrolandcomparison
conditions. Our combined therapy needs to be evaluated
against behavioral weight loss alone, as well as CBT for
depression alone, to determine whether the combination
treatment is superior to each monotherapy. A follow-up
assessment of 6–12 months also is needed to provide data
aboutthedurabilityofchangesinbothweightandsymptoms
of depression. A 1-year randomized controlled trial, with a
larger sample size, is the critical next step in establishing
the eﬃcacy of this treatment. In addition, our promis-
ing results require replication in a representative sample.
The current participants may reﬂect a subset of highly
motivated treatment-seeking individuals. These limitations
notwithstanding our combined treatment oﬀershope for the
large numbers of depressed, obese individuals who remain
without appropriate care.
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